Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • Sphere Fluidics, based in Cambridge, has received a  €1.6M grant from Eurostars to support the development of its DNA docking tech for genome editing.
  • Orchard Therapeutics extending is its collaboration with Manchester University to include Sanfilippo B Syndrome.

  • GSK has submitted a new drug application to the FDA for its malaria treatment to prevent relapse, which could be the first new treatment in 60 years.
  • Sotio started one of the notable biotechs in the Czech Republic, has a Phase II trial in ovarian cancer.
  • Merck missed its endpoint in a Phase III trial for a third-line gastric cancer treatment.

images via Sainam51, hkhtt hj, kunanon / shutterstock.com

SaveSave

Previous post

Could this Cancer Drug be Repurposed as the Next Big HIV Treatment?

Next post

The Door Opens for Dutch Brain Surgery Device to Enter the Clinic

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.